Form 4: Crinetics Pharmaceuticals CEO Exercises Stock Options, Maintains Significant Beneficial Ownership

Crinetics Pharmaceuticals' CEO, Richard Scott Struthers, exercised stock options and reported changes in his beneficial ownership of company stock, including holdings through family trusts and his spouse.

Summary

• On April 2, 2025, Richard Scott Struthers, the President and CEO of Crinetics Pharmaceuticals, exercised stock options to acquire 81,270 shares of common stock at a price of $1.91 per share.
• Following this transaction, Struthers directly owns 410,417 shares of Crinetics Pharmaceuticals' common stock.
• Struthers also has indirect beneficial ownership of shares held by family trusts, including 570,805 shares held by Family Trust 1, 110,000 shares each held by Family Trust 2 and Family Trust 3, and 100,000 shares held by Family Trust 4.
• Additionally, Struthers has indirect beneficial ownership of 1,000 shares held by his spouse.
• The exercised stock options were granted with 1/48th of the shares vesting on April 16, 2018, and 1/48th vesting monthly thereafter, contingent upon continued employment.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option exercises. While the CEO exercising options can be seen as a positive signal, the document itself is purely informational.

Positives

• The CEO's exercise of stock options could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the CEO's stake in the company.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased stake in the company.

Key Dates

Keywords

Crinetics Pharmaceuticals, Richard Scott Struthers, stock options, beneficial ownership, Form 4, CRNX, CEO, family trusts